Chemokines, chemokine receptors and the gastrointestinal system

World Journal of Gastroenterology

Volumn 19, Issue 19, 2013, Pages 2847-2863

  Miyazaki, Hiroshi ^a,b   Takabe, Kazuaki ^a   Andrew Yeudall, W ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cancer; Chemokine; Digestive system; Receptor; Signal transduction; Targeted therapeutics; Tumor progression

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CX3C CHEMOKINE; CXCL1 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 17; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER GROWTH; CELL HOMING; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; CROHN DISEASE; DIGESTIVE SYSTEM CANCER; ESOPHAGUS; GASTROINTESTINAL TRACT; HUMAN; LARGE INTESTINE; LIVER; METASTASIS; MOUTH CAVITY; NONHUMAN; PANCREAS; PANCREAS CANCER; REVIEW; SIGNAL TRANSDUCTION; SMALL INTESTINE; STOMACH; TUMOR CELL; UPREGULATION;

EID: 84878088779     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i19.2847     Document Type: Review

References (183)

1. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-463 [PMID: 15164071 DOI: 10.1038/nature02625]
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
3. Christofori G. New signals from the invasive front. Nature 2006; 441: 444-450 [PMID: 16724056 DOI: 10.1038/nature04872]
4. Alexiou C, Khan OA, Black E, Field ML, Onyeaka P, Beggs L, Duffy JP, Beggs DF. Survival after esophageal resection for carcinoma: the importance of the histologic cell type. Ann Thorac Surg 2006; 82: 1073-1077 [PMID: 16928541 DOI: 10.1016/j.athoracsur.2006.03.012]
5. Tait CR, Waterworth A, Loncaster J, Horgan K, Dodwell D. The oligometastatic state in breast cancer: hypothesis or reality. Breast 2005; 14: 87-93 [PMID: 15767177 DOI: 10.1016/ j.breast.2004.10.003]
6. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536 [PMID: 11823860 DOI: 10.1038/415530a]
7. Golan T, Javle M. Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology (Williston Park) 2011; 25: 518-26, 529 [PMID: 21717907]
8. Kim EJ, Zalupski MM. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. J Surg Oncol 2011; 104: 901-906 [PMID: 22069175 DOI: 10.1002/jso.21872]
9. Belinsky MG, Rink L, Cai KQ, Ochs MF, Eisenberg B, Huang M, von Mehren M, Godwin AK. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle 2008; 7: 2949-2955 [PMID: 18818517]
10. de Sousa EM, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res 2011; 17: 647-653 [PMID: 21159886 DOI: 10.1158/1078-0432. CCR-10-1204]
11. Grigoryan T, Wend P, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss-and gain-of-function mutations of beta-catenin in mice. Genes Dev 2008; 22: 2308-2341 [PMID: 18765787 DOI: 10.1101/gad.1686208]
12. Mosca M, Polentarutti N, Mangano G, Apicella C, Doni A, Mancini F, De Bortoli M, Coletta I, Polenzani L, Santoni G, Sironi M, Vecchi A, Mantovani A. Regulation of the microsomal prostaglandin E synthase-1 in polarized mononuclear phagocytes and its constitutive expression in neutrophils. J Leukoc Biol 2007; 82: 320-326 [PMID: 17505022 DOI: 10.1189/ jlb.0906576]
13. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899 [PMID: 20303878 DOI: 10.1016/j.cell.2010.01.025]
14. Groblewska M, Mroczko B, Szmitkowski M. [The role of selected matrix metalloproteinases and their inhibitors in colorectal cancer development]. Postepy Hig Med Dosw (Online) 2010; 64: 22-30 [PMID: 20173217]
15. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41: 2213-2236 [PMID: 16146690 DOI: 10.1016/j.ejca.2005.04.044]
16. Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev 2012; 31: 397-414 [PMID: 22527451 DOI: 10.1007/s10555-012-9351-2]
17. Nespoli L, Uggeri F, Romano F, Nespoli A, Brivo F, Fumagalli L, Sargenti M, Uggeri F, Gianotti L. Modulation of systemic and intestinal immune response by interleukin-2 therapy in gastrointestinal surgical oncology. Personal experience in the context of current knowledge and future perspectives. Anticancer Res 2012; 32: 989-996 [PMID: 22399622]
18. Moriasi C, Subramaniam D, Awasthi S, Ramalingam S, Anant S. Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor. Anticancer Agents Med Chem 2012; 12: 1221-1238 [PMID: 22583410]
19. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56 [PMID: 11242036 DOI: 10.1038/35065016]
20. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 2007; 109: 2392-2404 [PMID: 17503430 DOI: 10.1002/cncr.22706]
21. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-550 [PMID: 15229479 DOI: 10.1038/nrc1388]
22. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009; 4: e7965 [PMID: 19956757 DOI: 10.1371/journal.pone.0007965]
23. Barnas JL, Simpson-Abelson MR, Yokota SJ, Kelleher RJ, Bankert RB. T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron 2010; 3: 29-47 [PMID: 21209773 DOI: 10.1007/s12307-010-0044-5]
24. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684]
25. Yue ZQ, Liu YP, Ruan JS, Zhou L, Lu Y. Tumor-associated macrophages: a novel potential target for cancer treatment. Chin Med J (Engl) 2012; 125: 3305-3311 [PMID: 22964328]
26. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood 2009; 113: 3139-3146 [PMID: 19171876 DOI: 10.1182/blood-2008-12-172825]
27. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372-383 [PMID: 18799145 DOI: 10.1016/ j.immuni.2008.08.004]
28. Nardin A, Abastado JP. Macrophages and cancer. Front Biosci 2008; 13: 3494-3505 [PMID: 18508451]
29. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 2012; 18: 3831-3852 [PMID: 22632748]
30. Almholt K, Johnsen M. Stromal cell involvement in cancer. Recent Results Cancer Res 2003; 162: 31-42 [PMID: 12790319]
31. Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 2008; 216: 347-354 [PMID: 18481261 DOI: 10.1002/jcp.21494]
32. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127 [PMID: 10714678]
33. Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A, Maysushima K, Murphy P, Nomiyama H, Oppenheim J, Rot A, Schall T, Tsang M, Thorpe R, Van Damme J, Wadhwa M, Yoshie O, Zlotnik A, Zoon K. Chemokine/ chemokine receptor nomenclature. J Interferon Cytokine Res 2002; 22: 1067-1068 [PMID: 12433287]
34. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 2002; 42: 469-499 [PMID: 11807180 DOI: 10.1146/annurev.pharmtox.42.091901.115838]
35. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-1815 [PMID: 8525373]
36. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-242 [PMID: 10837058]
37. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002; 16: 1-4 [PMID: 11825560]
38. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928 [PMID: 15032599]
39. Parkinson EK, Graham GJ, Daubersies P, Burns JE, Heufler C, Plumb M, Schuler G, Pragnell IB. Hemopoietic stem cell inhibitor (SCI/MIP-1 alpha) also inhibits clonogenic epidermal keratinocyte proliferation. J Invest Dermatol 1993; 101: 113-117 [PMID: 8345211]
40. Rubie C, Frick VO, Wagner M, Schuld J, Gräber S, Brittner B, Bohle RM, Schilling MK. ELR+ CXC chemokine expression in benign and malignant colorectal conditions. BMC Cancer 2008; 8: 178 [PMID: 18578857 DOI: 10.1186/1471-2407-8-178]
41. Singh S, Wu S, Varney M, Singh AP, Singh RK. CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc Res 2011; 82: 318-325 [PMID: 21749879 DOI: 10.1016/j.mvr.2011.06.011]
42. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005; 175: 5351-5357 [PMID: 16210641]
43. Pappa CA, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, Xekalou A, Alegakis A, Boula A, Stathopoulos EN, Alexandrakis MG. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma. Cytokine 2011; 56: 616-620 [PMID: 21940178 DOI: 10.1016/ j.cyto.2011.08.034]
44. Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002; 54: 227-229 [PMID: 12037138]
45. Hurowitz EH, Melnyk JM, Chen YJ, Kouros-Mehr H, Simon MI, Shizuya H. Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes. DNA Res 2000; 7: 111-120 [PMID: 10819326]
46. Venkatakrishnan G, Salgia R, Groopman JE. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 2000; 275: 6868-6875 [PMID: 10702246]
47. Bonacchi A, Romagnani P, Romanelli RG, Efsen E, Annunziato F, Lasagni L, Francalanci M, Serio M, Laffi G, Pinzani M, Gentilini P, Marra F. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 2001; 276: 9945-9954 [PMID: 11136732]
48. Chandrasekar B, Melby PC, Sarau HM, Raveendran M, Perla RP, Marelli-Berg FM, Dulin NO, Singh IS. Chemokinecytokine cross-talk. The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-kappa B pathway. J Biol Chem 2003; 278: 4675-4686 [PMID: 12468547]
49. Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem 2004; 279: 3188-3196 [PMID: 14625285]
50. Schraufstatter IU, Chung J, Burger M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1094-L1103 [PMID: 11350788]
51. Wang D, Sai J, Carter G, Sachpatzidis A, Lolis E, Richmond A. PAK1 kinase is required for CXCL1-induced chemotaxis. Biochemistry 2002; 41: 7100-7107 [PMID: 12033944]
52. Tan W, Martin D, Gutkind JS. The Galpha13-Rho signaling axis is required for SDF-1-induced migration through CXCR4. J Biol Chem 2006; 281: 39542-39549 [PMID: 17056591 DOI: 10.1074/jbc.M609062200]
53. Liu-Bryan R, Pay S, Schraufstatter IU, Rose DM. The CXCR1 tail mediates beta1 integrin-dependent cell migration via MAP kinase signaling. Biochem Biophys Res Commun 2005; 332: 117-125 [PMID: 15896307]
54. Van Damme J, Struyf S, Opdenakker G. Chemokine-protease interactions in cancer. Semin Cancer Biol 2004; 14: 201-208 [PMID: 15246056]
55. Muñoz LM, Holgado BL, Martínez A C, Rodríguez-Frade JM, Mellado M. Chemokine receptor oligomerization: a further step toward chemokine function. Immunol Lett 2012; 145: 23-29 [PMID: 22698180 DOI: 10.1016/j.imlet.2012.04.012]
56. Gill GN, Lazar CS. Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature 1981; 293: 305-307 [PMID: 6268987]
57. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002; 72: 9-18 [PMID: 12101257]
58. Balentien E, Mufson BE, Shattuck RL, Derynck R, Richmond A. Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene 1991; 6: 1115-1124 [PMID: 1861861]
59. Zhou Y, Zhang J, Liu Q, Bell R, Muruve DA, Forsyth P, Arcellana-Panlilio M, Robbins S, Yong VW. The chemokine GROalpha (CXCL1) confers increased tumorigenicity to glioma cells. Carcinogenesis 2005; 26: 2058-2068 [PMID: 16033775]
60. Metzner B, Hofmann C, Heinemann C, Zimpfer U, Schraufstätter I, Schöpf E, Norgauer J. Overexpression of CXCchemokines and CXC-chemokine receptor type II constitute an autocrine growth mechanism in the epidermoid carcinoma cells KB and A431. Oncol Rep 1999; 6: 1405-1410 [PMID: 10523720]
61. Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 2006; 66: 3071-3077 [PMID: 16540656]
62. Feng G, Ohmori Y, Chang PL. Production of chemokine CXCL1/KC by okadaic acid through the nuclear factor-kappaB pathway. Carcinogenesis 2006; 27: 43-52 [PMID: 16000401]
63. Dhawan P, Richmond A. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 2002; 277: 7920-7928 [PMID: 11773061]
64. Amiri KI, Ha HC, Smulson ME, Richmond A. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Oncogene 2006; 25: 7714-7722 [PMID: 16799643]
65. Miller LJ, Kurtzman SH, Wang Y, Anderson KH, Lindquist RR, Kreutzer DL. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res 1998; 18: 77-81 [PMID: 9568059]
66. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004; 14: 171-179 [PMID: 15246052]
67. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002; 62: 7203-7206 [PMID: 12499259]
68. Brown MJ, Nijhara R, Hallam JA, Gignac M, Yamada KM, Erlandsen SL, Delon J, Kruhlak M, Shaw S. Chemokine stimulation of human peripheral blood T lymphocytes induces rapid dephosphorylation of ERM proteins, which facilitates loss of microvilli and polarization. Blood 2003; 102: 3890-3899 [PMID: 12907449]
69. Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004; 84: 1666-1676 [PMID: 15467730]
70. Zhang J, Sarkar S, Yong VW. The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase. Carcinogenesis 2005; 26: 2069-2077 [PMID: 16033774]
71. Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO, Castillo SS, Dennis PA, Hwang ST. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med 2003; 198: 1337-1347 [PMID: 14581607]
72. Simonetti O, Goteri G, Lucarini G, Filosa A, Pieramici T, Rubini C, Biagini G, Offidani A. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur J Cancer 2006; 42: 1181-1187 [PMID: 16644201]
73. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5: 1597-1601 [PMID: 16880743]
74. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348 [PMID: 15882617]
75. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002; 32: 355-357 [PMID: 12379854]
76. Paterson RF, Ulbright TM, MacLennan GT, Zhang S, Pan CX, Sweeney CJ, Moore CR, Foster RS, Koch MO, Eble JN, Cheng L. Molecular genetic alterations in the laser-capturemicrodissected stroma adjacent to bladder carcinoma. Cancer 2003; 98: 1830-1836 [PMID: 14584063]
77. Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi MY, Chapman CG, Wang H, Black E, Bulysheva AA, Deb SP, Windle B, Deb S. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 2012; 33: 442-451 [PMID: 22114072 DOI: 10.1093/ carcin/bgr270]
78. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, Al-Mehdi AB, Bernhard EJ, Muschel RJ. Apoptosis: an early event in metastatic inefficiency. Cancer Res 2001; 61: 333-338 [PMID: 11196183]
79. Kassenbrock CK, Hunter S, Garl P, Johnson GL, Anderson SM. Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor. J Biol Chem 2002; 277: 24967-24975 [PMID: 11994282]
80. Swan EA, Jasser SA, Holsinger FC, Doan D, Bucana C, Myers JN. Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol 2003; 39: 648-655 [PMID: 12907203]
81. Sánchez-Sánchez N, Riol-Blanco L, de la Rosa G, Puig-Kröger A, García-Bordas J, Martín D, Longo N, Cuadrado A, Cabañas C, Corbí AL, Sánchez-Mateos P, Rodríguez-Fernández JL. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood 2004; 104: 619-625 [PMID: 15059845]
82. Youngs SJ, Ali SA, Taub DD, Rees RC. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 1997; 71: 257-266 [PMID: 9139852]
83. Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P, Cheng N. CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 proteinand p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem 2012; 287: 36593-36608 [PMID: 22927430 DOI: 10.1074/jbc.M112.365999]
84. Barretina J, Juncà J, Llano A, Gutiérrez A, Flores A, Blanco J, Clotet B, Esté JA. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann Hematol 2003; 82: 500-505 [PMID: 12783211 DOI: 10.1007/ s00277-003-0679-0]
85. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000; 96: 2655-2663 [PMID: 11023495]
86. O'Hayre M, Salanga CL, Kipps TJ, Messmer D, Dorrestein PC, Handel TM. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS One 2010; 5: e11716 [PMID: 20661426 DOI: 10.1371/journal.pone.0011716]
87. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936 [PMID: 16355210]
88. Komatsu M, Ruoslahti E. R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat Med 2005; 11: 1346-1350 [PMID: 16286923 DOI: 10.1038/nm1324]
89. Sawada J, Urakami T, Li F, Urakami A, Zhu W, Fukuda M, Li DY, Ruoslahti E, Komatsu M. Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell 2012; 22: 235-249 [PMID: 22897853 DOI: 10.1016/j.ccr.2012. 06.013]
90. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801 [PMID: 1281554]
91. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006; 66: 11238-11246 [PMID: 17114237]
92. Heidemann J, Ogawa H, Dwinell MB, Rafiee P, Maaser C, Gockel HR, Otterson MF, Ota DM, Lugering N, Domschke W, Binion DG. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 2003; 278: 8508-8515 [PMID: 12496258]
93. Sodhi A, Montaner S, Patel V, Gómez-Román JJ, Li Y, Sausville EA, Sawai ET, Gutkind JS. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirusencoded G protein-coupled receptor. Proc Natl Acad Sci U S A 2004; 101: 4821-4826 [PMID: 15047889]
94. Sun Q, Matta H, Lu G, Chaudhary PM. Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappaB activation. Oncogene 2006; 25: 2717-2726 [PMID: 16418726]
95. Montaner S, Kufareva I, Abagyan R, Gutkind JS. Molecular mechanisms deployed by virally encoded G proteincoupled receptors in human diseases. Annu Rev Pharmacol Toxicol 2013; 53: 331-354 [PMID: 23092247 DOI: 10.1146/ annurev-pharmtox-010510-100608]
96. Strieter RM, Belperio JA, Phillips RJ, Keane MP. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 2004; 14: 195-200 [PMID: 15246055]
97. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio M. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001; 107: 53-63 [PMID: 11134180]
98. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197: 1537-1549 [PMID: 12782716]
99. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology 2011; 81 Suppl 1: 24-29 [PMID: 22212932 DOI: 10.1159/000333256]
100. Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, Schirlau K, Franken-Kunkel P, Poremba C, Snyderman C, Klotz LO, Ruzicka T, Bier H, Zlotnik A, Whiteside TL, Homey B, Hoffmann TK. Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer 2006; 118: 2147-2157 [PMID: 16331601 DOI: 10.1002/ijc.21514]
101. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078]
102. McMahon S, Chen AY. Head and neck cancer. Cancer Metastasis Rev 2003; 22: 21-24 [PMID: 12716033]
103. Shintani S, Ishikawa T, Nonaka T, Li C, Nakashiro K, Wong DT, Hamakawa H. Growth-regulated oncogene-1 expression is associated with angiogenesis and lymph node metastasis in human oral cancer. Oncology 2004; 66: 316-322 [PMID: 15218300]
104. Miyazaki H, Patel V, Wang H, Ensley JF, Gutkind JS, Yeudall WA. Growth factor-sensitive molecular targets identified in primary and metastatic head and neck squamous cell carcinoma using microarray analysis. Oral Oncol 2006; 42: 240-256 [PMID: 16266819]
105. Chen W, Kajiya M, Giro G, Ouhara K, Mackler HE, Mawardi H, Boisvert H, Duncan MJ, Sato K, Kawai T. Bacteriaderived hydrogen sulfide promotes IL-8 production from epithelial cells. Biochem Biophys Res Commun 2010; 391: 645-650 [PMID: 19932683 DOI: 10.1016/j.bbrc.2009.11.113]
106. Meyer C, Pries R, Wollenberg B. Established and novel NF-κB inhibitors lead to downregulation of TLR3 and the proliferation and cytokine secretion in HNSCC. Oral Oncol 2011; 47: 818-826 [PMID: 21745758 DOI: 10.1016/j.oraloncology. 2011.06.010]
107. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res 2006; 66: 4279-4284 [PMID: 16618752]
108. Delilbasi CB, Okura M, Iida S, Kogo M. Investigation of CXCR4 in squamous cell carcinoma of the tongue. Oral Oncol 2004; 40: 154-157 [PMID: 14693238]
109. Clatot F, Picquenot JM, Choussy O, Gouérant S, Moldovan C, Schultheis D, Cornic M, François A, Blot E, Laberge-Le-Couteulx S. Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncol 2011; 47: 1062-1068 [PMID: 21840752 DOI: 10.1016/ j.oraloncology.2011.07.021]
110. Wang J, Xi L, Hunt JL, Gooding W, Whiteside TL, Chen Z, Godfrey TE, Ferris RL. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 2004; 64: 1861-1866 [PMID: 14996750]
111. Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, Chen ZG, Ferris RL. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene 2005; 24: 5897-5904 [PMID: 16007209 DOI: 10.1038/ sj.onc.1208740]
112. Rieder F, Biancani P, Harnett K, Yerian L, Falk GW. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2010; 298: G571-G581 [PMID: 20299604 DOI: 10.1152/ajpgi.00454.2009]
113. Oh DS, DeMeester SR, Vallbohmer D, Mori R, Kuramochi H, Hagen JA, Lipham J, Danenberg KD, Danenberg PV, Chandrasoma P, DeMeester TR. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. Arch Surg 2007; 142: 554-59; discussion 554-59; [PMID: 17576892 DOI: 10.1001/archsurg. 142.6.554]
114. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, Banas T. Impact of weight loss on circulating IL-1, IL-6, IL-8, TNFalpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin Biochem 2007; 40: 1353-1360 [PMID: 17931612 DOI: 10.1016/j.clinbiochem.2007.07.013]
115. Verbeke H, De Hertogh G, Li S, Vandercappellen J, Noppen S, Schutyser E, El-Asrar AA, Opdenakker G, Van Damme J, Geboes K, Struyf S. Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer. Hum Pathol 2010; 41: 990-1001 [PMID: 20334899 DOI: 10.1016/j.humpath.2009.09.021]
116. Gros SJ, Kurschat N, Drenckhan A, Dohrmann T, Forberich E, Effenberger K, Reichelt U, Hoffman RM, Pantel K, Kaifi JT, Izbicki JR. Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PLoS One 2012; 7: e47287 [PMID: 23082154 DOI: 10.1371/journal. pone.0047287]
117. Hashimoto I, Koizumi K, Tatematsu M, Minami T, Cho S, Takeno N, Nakashima A, Sakurai H, Saito S, Tsukada K, Saiki I. Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer 2008; 44: 1022-1029 [PMID: 18375114 DOI: 10.1016/ j.ejca.2008.02.043]
118. Koizumi K, Kato S, Sakurai H, Hashimoto I, Yasumoto K, Saiki I. Therapeutics target of CXCR4 and its downstream in peritoneal carcinomatosis of gastric cancer. Front Biosci (Schol Ed) 2012; 4: 269-276 [PMID: 22202059]
119. Graziosi L, Mencarelli A, Santorelli C, Renga B, Cipriani S, Cavazzoni E, Palladino G, Laufer S, Burnet M, Donini A, Fiorucci S. Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. Eur J Pharmacol 2012; 674: 143-152 [PMID: 22119383 DOI: 10.1016/ j.ejphar.2011.11.015]
120. Zhi Y, Chen J, Zhang S, Chang X, Ma J, Dai D. Downregulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression. Dig Dis Sci 2012; 57: 650-659 [PMID: 21960286 DOI: 10.1007/ s10620-011-1922-5]
121. Manu KA, Shanmugam MK, Rajendran P, Li F, Ramachandran L, Hay HS, Kannaiyan R, Swamy SN, Vali S, Kapoor S, Ramesh B, Bist P, Koay ES, Lim LH, Ahn KS, Kumar AP, Sethi G. Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol Cancer 2011; 10: 107 [PMID: 21880153 DOI: 10.1186/1476-4598-10-107]
122. Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, Zhao J, Meng YL, Ren XL, Wang T, Li Q, Jin BQ, Yao LB, Wang RA, Fan DM, Chen SY, Jia LT, Yang AG. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 2011; 141: 2076-2087. e6 [PMID: 21925125 DOI: 10.1053/j.gastro. 2011.08.050]
123. Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res 2011; 17: 3619-3630 [PMID: 21482691 DOI: 10.1158/1078-0432. CCR-10-2475]
124. Zhao BC, Wang ZJ, Mao WZ, Ma HC, Han JG, Zhao B, Xu HM. CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol 2011; 17: 2389-2396 [PMID: 21633638 DOI: 10.3748/wjg.v17.i19.2389]
125. Ingold B, Simon E, Ungethüm U, Kuban RJ, Müller BM, Lupp A, Neumann U, Ebert MP, Denkert C, Weichert W, Schulz S, Röcken C. Vascular CXCR4 expression-a novel antiangiogenic target in gastric cancer? PLoS One 2010; 5: e10087 [PMID: 20386750 DOI: 10.1371/journal.pone.0010087]
126. Xu J, Zhang C, He Y, Wu H, Wang Z, Song W, Li W, He W, Cai S, Zhan W. Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer 2012; 130: 787-797 [PMID: 21387301 DOI: 10.1002/ijc.26035]
127. Han L, Jiang B, Wu H, Wang X, Tang X, Huang J, Zhu J. High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma. Med Oncol 2012; 29: 2466-2472 [PMID: 22274915 DOI: 10.1007/s12032-011-0152-1]
128. Liu Z, Yang L, Xu J, Zhang X, Wang B. Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma. J Surg Res 2011; 166: 241-246 [PMID: 20018298 DOI: 10.1016/j.jss.2009.07.014]
129. Kitadai Y, Kodama M, Cho S, Kuroda T, Ochiumi T, Kimu-ra S, Tanaka S, Matsumura S, Yasui W, Chayama K. Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int J Cancer 2005; 115: 388-392 [PMID: 15688374 DOI: 10.1002/ ijc.20859]
130. Gao P, Zhou GY, Zhang QH, Su ZX, Zhang TG, Xiang L, Wang Y, Zhang SL, Mu K. Lymphangiogenesis in gastric carcinoma correlates with prognosis. J Pathol 2009; 218: 192-200 [PMID: 19224540 DOI: 10.1002/path.2523]
131. Ju D, Sun D, Xiu L, Meng X, Zhang C, Wei P. Interleukin-8 is associated with adhesion, migration and invasion in human gastric cancer SCG-7901 cells. Med Oncol 2012; 29: 91-99 [PMID: 21191670 DOI: 10.1007/s12032-010-9780-0]
132. Wang J, Pan HF, Hu YT, Zhu Y, He Q. Polymorphism of IL-8 in 251 allele and gastric cancer susceptibility: a metaanalysis. Dig Dis Sci 2010; 55: 1818-1823 [PMID: 19777350 DOI: 10.1007/s10620-009-0978-y]
133. Song JH, Kim SG, Jung SA, Lee MK, Jung HC, Song IS. The interleukin-8-251 AA genotype is associated with angiogenesis in gastric carcinogenesis in Helicobacter pylori-infected Koreans. Cytokine 2010; 51: 158-165 [PMID: 20621718 DOI: 10.1016/j.cyto.2010.05.001]
134. Vinagre RM, Corvelo TC, Arnaud VC, Leite AC, Barile KA, Martins LC. Determination of strains of Helicobacter pylori and of polymorphism in the interleukin-8 gene in patients with stomach cancer. Arq Gastroenterol 2011; 48: 46-51 [PMID: 21537542]
135. Schneider S, Carra G, Sahin U, Hoy B, Rieder G, Wessler S. Complex cellular responses of Helicobacter pylori-colonized gastric adenocarcinoma cells. Infect Immun 2011; 79: 2362-2371 [PMID: 21402757 DOI: 10.1128/IAI.01350-10]
136. Liu L, Zhuang W, Wang C, Chen Z, Wu XT, Zhou Y. Interleukin-8-251 A/T gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiological studies. Cytokine 2010; 50: 328-334 [PMID: 20363644 DOI: 10.1016/ j.cyto.2010.03.008]
137. Park JY, Park KH, Bang S, Kim MH, Lee JE, Gang J, Koh SS, Song SY. CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol 2007; 133: 835-840 [PMID: 17479287 DOI: 10.1007/s00432-007-0225-x]
138. Frick VO, Rubie C, Wagner M, Graeber S, Grimm H, Kopp B, Rau BM, Schilling MK. Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases. Pancreatology 2008; 8: 488-497 [PMID: 18765953 DOI: 10.1159/000151776]
139. Yanagie H, Hisa T, Ono M, Eriguchi M. [Chemokine and chemokine receptor related to cancer metastasis]. Gan To Kagaku Ryoho 2010; 37: 2052-2057 [PMID: 21084802]
140. Verbeke H, Geboes K, Van Damme J, Struyf S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta 2012; 1825: 117-129 [PMID: 22079531 DOI: 10.1016/ j.bbcan.2011.10.008]
141. Huang F, Geng XP. Chemokines and hepatocellular carcinoma. World J Gastroenterol 2010; 16: 1832-1836 [PMID: 20397259]
142. Furusato B, Mohamed A, Uhlén M, Rhim JS. CXCR4 and cancer. Pathol Int 2010; 60: 497-505 [PMID: 20594270 DOI: 10.1111/j.1440-1827.2010.02548.x]
143. Li N, Guo W, Shi J, Xue J, Hu H, Xie D, Wu M, Cheng S. Expression of the chemokine receptor CXCR4 in human hepatocellular carcinoma and its role in portal vein tumor thrombus. J Exp Clin Cancer Res 2010; 29: 156 [PMID: 21110890 DOI: 10.1186/1756-9966-29-156]
144. Tsuchiyama T, Kaneko S, Nakamoto Y, Sakai Y, Honda M, Mukaida N, Kobayashi K. Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Ther 2003; 10: 260-269 [PMID: 12679798 DOI: 10.1038/ sj.cgt.7700571]
145. Sakai Y, Kaneko S, Nakamoto Y, Kagaya T, Mukaida N, Kobayashi K. Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma. Cancer Gene Ther 2001; 8: 695-704 [PMID: 11687892 DOI: 10.1038/sj.cgt.7700360]
146. Kakinoki K, Nakamoto Y, Kagaya T, Tsuchiyama T, Sakai Y, Nakahama T, Mukaida N, Kaneko S. Prevention of intrahepatic metastasis of liver cancer by suicide gene therapy and chemokine ligand 2/monocyte chemoattractant protein-1 delivery in mice. J Gene Med 2010; 12: 1002-1013 [PMID: 21157824 DOI: 10.1002/jgm.1528]
147. Chen TA, Wang JL, Hung SW, Chu CL, Cheng YC, Liang SM. Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production. PLoS One 2011; 6: e23317 [PMID: 21826248 DOI: 10.1371/journal.pone.0023317]
148. Monnier J, Boissan M, L'Helgoualc'h A, Lacombe ML, Turlin B, Zucman-Rossi J, Théret N, Piquet-Pellorce C, Samson M. CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur J Cancer 2012; 48: 138-148 [PMID: 21778049 DOI: 10.1016/j.ejca.2011.06.044]
149. Zheng K, Li HY, Su XL, Wang XY, Tian T, Li F, Ren GS. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010; 29: 31 [PMID: 20380740 DOI: 10.1186/1756-9966-29-31]
150. Gassmann P, Haier J, Schlüter K, Domikowsky B, Wendel C, Wiesner U, Kubitza R, Engers R, Schneider SW, Homey B, Müller A. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia 2009; 11: 651-661 [PMID: 19568410]
151. Holt AP, Haughton EL, Lalor PF, Filer A, Buckley CD, Adams DH. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology 2009; 136: 705-714 [PMID: 19010327 DOI: 10.1053/ j.gastro.2008.10.020]
152. Abiko Y, Nishimura M, Kusano K, Nakashima K, Okumura K, Arakawa T, Takuma T, Mizoguchi I, Kaku T. Expression of MIP-3alpha/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma. Arch Oral Biol 2003; 48: 171-175 [PMID: 12642237]
153. Ghadjar P, Coupland SE, Na IK, Noutsias M, Letsch A, Stroux A, Bauer S, Buhr HJ, Thiel E, Scheibenbogen C, Keilholz U. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 2006; 24: 1910-1916 [PMID: 16622267 DOI: 10.1200/JCO.2005.04.1822]
154. Rubie C, Frick VO, Ghadjar P, Wagner M, Grimm H, Vicinus B, Justinger C, Graeber S, Schilling MK. CCL20/CCR6 expression profile in pancreatic cancer. J Transl Med 2010; 8: 45 [PMID: 20459729 DOI: 10.1186/1479-5876-8-45]
155. Rubie C, Frick VO, Wagner M, Rau B, Weber C, Kruse B, Kempf K, Tilton B, König J, Schilling M. Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma. Scand J Immunol 2006; 63: 468-477 [PMID: 16764701 DOI: 10.1111/j.1365-3083.2006.001766.x]
156. Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM, Burdick M, Go VL, Reber HA, Eibl G, Hines OJ. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol 2011; 178: 1340-1349 [PMID: 21356384 DOI: 10.1016/ j.ajpath.2010.11.058]
157. Hussain F, Wang J, Ahmed R, Guest SK, Lam EW, Stamp G, El-Bahrawy M. The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine 2010; 49: 134-140 [PMID: 20005738 DOI: 10.1016/j.cyto.2009.11.010]
158. Cui K, Zhao W, Wang C, Wang A, Zhang B, Zhou W, Yu J, Sun Z, Li S. The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J Surg Res 2011; 171: 143-150 [PMID: 20462600 DOI: 10.1016/j.jss.2010.03.001]
159. Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR, Bockhorn M. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol 2011; 104: 140-145 [PMID: 21520098 DOI: 10.1002/jso.21957]
160. Yadav VR, Sung B, Prasad S, Kannappan R, Cho SG, Liu M, Chaturvedi MM, Aggarwal BB. Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med (Berl) 2010; 88: 1243-1253 [PMID: 20798912 DOI: 10.1007/s00109-010-0669-3]
161. Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 2010; 103: 1671-1679 [PMID: 21045835 DOI: 10.1038/sj.bjc.6605968]
162. Chua AW, Hay HS, Rajendran P, Shanmugam MK, Li F, Bist P, Koay ES, Lim LH, Kumar AP, Sethi G. Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-κB activation in breast and pancreatic tumor cells. Biochem Pharmacol 2010; 80: 1553-1562 [PMID: 20699088 DOI: 10.1016/j.bcp.2010.07.045]
163. Marchesi F, Locatelli M, Solinas G, Erreni M, Allavena P, Mantovani A. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J Neuroimmunol 2010; 224: 39-44 [PMID: 20630606 DOI: 10.1016/j.jneuroim.2010.05.007]
164. Marchesi F, Piemonti L, Mantovani A, Allavena P. Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine Growth Factor Rev 2010; 21: 77-82 [PMID: 20060768 DOI: 10.1016/j.cytogfr. 2009.11.001]
165. D'Haese JG, Demir IE, Friess H, Ceyhan GO. Fractalkine/ CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets 2010; 14: 207-219 [PMID: 20055718 DOI: 10.1517/147 28220903540265]
166. Pierantoni C, Pagliacci A, Scartozzi M, Berardi R, Bianconi M, Cascinu S. Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol 2008; 67: 27-38 [PMID: 18356073 DOI: 10.1016/j.critrevonc.2008.01.009]
167. Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S, Kanai Y. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 2011; 140: 310-321 [PMID: 20955708 DOI: 10.1053/j.gastro.2010.10.009]
168. Matsubara J, Honda K, Ono M, Tanaka Y, Kobayashi M, Jung G, Yanagisawa K, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T, Hirohashi S, Yamada T. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 160-171 [PMID: 21148121 DOI: 10.1158/1055-9965.EPI-10-0397]
169. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N. Blocking TNFalpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118: 560-570 [PMID: 18219394 DOI: 10.1172/JCI32453]
170. Vetrano S, Borroni EM, Sarukhan A, Savino B, Bonecchi R, Correale C, Arena V, Fantini M, Roncalli M, Malesci A, Mantovani A, Locati M, Danese S. The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. Gut 2010; 59: 197-206 [PMID: 19846409 DOI: 10.1136/gut.2009.183772]
171. Berres ML, Trautwein C, Zaldivar MM, Schmitz P, Pauels K, Lira SA, Tacke F, Wasmuth HE. The chemokine scavenging receptor D6 limits acute toxic liver injury in vivo. Biol Chem 2009; 390: 1039-1045 [PMID: 19642876 DOI: 10.1515/ BC.2009.119]
172. Nibbs RJ, Kriehuber E, Ponath PD, Parent D, Qin S, Campbell JD, Henderson A, Kerjaschki D, Maurer D, Graham GJ, Rot A. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol 2001; 158: 867-877 [PMID: 11238036]
173. Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, Wada T, Egashira K, Mukaida N. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 2009; 69: 7884-7892 [PMID: 19773434 DOI: 10.1158/0008-5472.CAN-09-1451]
174. Noronha AM, Liang Y, Hetzel JT, Hasturk H, Kantarci A, Stucchi A, Zhang Y, Nikolajczyk BS, Farraye FA, Ganley-Leal LM. Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol 2009; 86: 1007-1016 [PMID: 19589946 DOI: 10.1189/jlb.0309203]
175. Im E, Choi YJ, Kim CH, Fiocchi C, Pothoulakis C, Rhee SH. The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8. Am J Physiol Gastrointest Liver Physiol 2009; 297: G999-G1008 [PMID: 20501448]
176. Lopez M, Li N, Kataria J, Russell M, Neu J. Live and ultraviolet-inactivated Lactobacillus rhamnosus GG decrease flagellin-induced interleukin-8 production in Caco-2 cells. J Nutr 2008; 138: 2264-2268 [PMID: 18936229 DOI: 10.3945/ jn.108.093658]
177. Zhang L, Li N, Caicedo R, Neu J. Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alphainduced interleukin-8 production in Caco-2 cells. J Nutr 2005; 135: 1752-1756 [PMID: 15987860]
178. Tanaka Y, Sekiguchi F, Hong H, Kawabata A. PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells. Biochem Biophys Res Commun 2008; 377: 622-626 [PMID: 18854173 DOI: 10.1016/j.bbrc.2008.10.018]
179. Arijs I, De Hertogh G, Machiels K, Van Steen K, Lemaire K, Schraenen A, Van Lommel L, Quintens R, Van Assche G, Vermeire S, Schuit F, Rutgeerts P. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol 2011; 106: 748-761 [PMID: 21326222 DOI: 10.1038/ajg.2011.27]
180. Oladipo O, Conlon S, O'Grady A, Purcell C, Wilson C, Maxwell PJ, Johnston PG, Stevenson M, Kay EW, Wilson RH, Waugh DJ. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer 2011; 104: 480-487 [PMID: 21285972 DOI: 10.1038/sj.bjc.6606055]
181. Schroepf S, Kappler R, Brand S, Prell C, Lohse P, Glas J, Hoster E, Helmbrecht J, Ballauff A, Berger M, von Schweinitz D, Koletzko S, Lacher M. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1882-1890 [PMID: 20848514 DOI: 10.1002/ibd.21312]
182. Lee JW, Wang P, Kattah MG, Youssef S, Steinman L, DeFea K, Straus DS. Differential regulation of chemokines by IL-17 in colonic epithelial cells. J Immunol 2008; 181: 6536-6545 [PMID: 18941244]
183. Ju DW, Wei PK, Lin HM, Sun DZ, Yu S, Xiu LJ. [Effects of Xiaotan Sanjie Decoction on expressions of interleukin-8 and its receptors in gastric tumor xenografts and gastric tissue adjacent to the tumor in mice]. Zhongxiyi Jiehe Xuebao 2010; 8: 74-79 [PMID: 20082763]